Tech Company Financing Transactions

ILiAD Biotechnologies Funding Round

ILiAD Biotechnologies, operating out of New York, secured $42.8 million from Knott Partners and private investors.

Transaction Overview

Announced On
9/6/2022
Transaction Type
Venture Equity
Amount
$42,800,000
Round
Series D
Investors

Knott Partners (Lead Investor)

Proceeds Purpose
The company intends to use the funds to conduct a Phase 2b Human Challenge study to determine if vaccination with BPZE1 prevents colonization from wild-type Bordetella pertussis infection.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
230 East 15th St. 1-A
New York, NY 10003
USA
Email Address
Overview
ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate is BPZE1, a live attenuated pertussis vaccine that is currently in Phase 2 and has successfully completed two Phase 1 human clinical trials.
Profile
ILiAD Biotechnologies LinkedIn Company Profile
Social Media
ILiAD Biotechnologies Company Twitter Account
Company News
ILiAD Biotechnologies News
Facebook
ILiAD Biotechnologies on Facebook
YouTube
ILiAD Biotechnologies on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Keith Rubin
  Keith Rubin LinkedIn Profile  Keith Rubin Twitter Account  Keith Rubin News  Keith Rubin on Facebook
Chief Financial Officer
Walter Greenblatt
  Walter Greenblatt LinkedIn Profile  Walter Greenblatt Twitter Account  Walter Greenblatt News  Walter Greenblatt on Facebook
Chief Operating Officer
Ken Solovay
  Ken Solovay LinkedIn Profile  Ken Solovay Twitter Account  Ken Solovay News  Ken Solovay on Facebook
Controller
James Ramadei
  James Ramadei LinkedIn Profile  James Ramadei Twitter Account  James Ramadei News  James Ramadei on Facebook
General Manager
Marcel Thalen
  Marcel Thalen LinkedIn Profile  Marcel Thalen Twitter Account  Marcel Thalen News  Marcel Thalen on Facebook
Vice President
Stanley Kim
  Stanley Kim LinkedIn Profile  Stanley Kim Twitter Account  Stanley Kim News  Stanley Kim on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/6/2022: Gig and Take venture capital transaction
Next: 9/6/2022: Credix Finance venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary